The company projects total turnover of around RON750 million (EUR151.5 million) at group level in 2023.
This year, a possible challenging situation on the market is likely to be brought about by the price policy in Romania, which in 2022 upended the procurement of certain molecules.
The company in 2022 invested around RON3.3 million in equipment, technology, digitalization and security.
In 2023, it plans to continue investments in tehnology, equipment, digitalization, with RON4.5 million earmarked for the projects. In the first quarter, Bioeel completed the acquisition of an around 4,000-sqm warehouse.
(English version by Catalina Apostoiu)